Finance

Lists
Q2 2026 earnings • released • EPS beat +2.87% • Revenue beat +4.44%
See results
LYEL:NASDAQ
Lyell Immunopharma Inc
$14.71
+3.52%
(+0.50) 1D
$15.00
+1.97% (+0.29)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LYEL...
Open
$14.00
High
$15.09
Low
$13.94
Mkt. cap
343.24M
Avg. vol.
235.94K
Volume
111.17K
52-wk high
$45.00
52-wk low
$9.28
EPS
-$12.98
Beta
-0.04
Shares outstanding
24.50M
No. of employees
161
Open
$14.00
High
$15.09
Low
$13.94
Mkt. cap
343.24M
Avg. vol.
235.94K
Volume
111.17K
52-wk high
$45.00
52-wk low
$9.28
EPS
-$12.98
Beta
-0.04
Shares outstanding
24.50M
No. of employees
161
News stories
From sources across the web
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitelyell.com
Analyst ratings
Based on 5 analysts giving stock ratings to LYEL in the past 3 months
Buy
Buy
4
Hold
0
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for LYEL in the last 3 months.
Highest
Current $14.71
$45.00 (+205.91%)
Average
$36.20 (+146.09%)
Lowest
$12.00 (-18.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+205.9%
08/07/2026
Gil Blum
Needham
Buy
Maintained
$44.00
+199.1%
08/07/2026
Stephen Willey
Stifel Nicolaus
Buy
Initiated
$36.00
+144.7%
08/06/2026
Yuan Zhi
B. Riley Securities
Buy
Initiated
$44.00
+199.1%
07/22/2026
Jason Zemansky
Bank of America Securities
Sell
Reiterated
$12.00
-18.4%
06/03/2026
Jack Allen
Robert W. Baird
Buy
Initiated
$49.00
+233.1%
05/01/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$34.00
+131.1%
03/09/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.74 / -$1.79
+2.87%beat
Revenue / Est. (USD)
4.00K / 3.83K
+4.44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.00K
6.00K
2.00K
4.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.17M
52.20M
36.60M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.69M
10.62M
9.56M
-
Operating expense
37.27M
61.48M
44.26M
-
Total operating expenses
37.27M
61.48M
44.26M
-
Operating income
-37.25M
-61.48M
-44.26M
-
Other non operating income
-4.86M
-17.46M
17.91M
-
EBT including unusual items
-38.85M
-140.72M
-24.15M
-
EBT excluding unusual items
-38.85M
-76.26M
-24.15M
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-1.59M
-1.33M
-1.90M
-1.76M
Net income
-38.85M
-140.72M
-24.15M
-
Net profit margin
-258,973.33%
-2,345,383.33%
-1,207,650.00%
-
Earnings per share
-
-
-
-1.74
Interest and investment income
3.27M
2.68M
2.19M
-
Interest expense
-
-
-
-
Net interest expenses
3.27M
2.68M
2.19M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.69M
-59.08M
-41.93M
-
Gain or loss from assets sale
-249.00K
-166.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps